Strong On High Relative Volume: SciClone Pharmaceuticals (SCLN)

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Trade-Ideas LLC identified SciClone Pharmaceuticals ( SCLN) as a strong on high relative volume candidate. In addition to specific proprietary factors, Trade-Ideas identified SciClone Pharmaceuticals as such a stock due to the following factors:

  • SCLN has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $3.0 million.
  • SCLN has traded 61,784 shares today.
  • SCLN is trading at 2.51 times the normal volume for the stock at this time of day.
  • SCLN is trading at a new high 5.13% above yesterday's close.

'Strong on High Relative Volume' stocks are worth watching because major volume moves tend to indicate underlying activity such as M&A events, material stock news, analyst upgrades, insider buying, buying from 'superinvestors,' or that hedge funds and momentum traders are piling into a stock ahead of a catalyst. Regardless of the impetus behind the price and volume action, when a stock moves with strength and volume it can indicate the start of a new trend on which early investors can capitalize. In the event of a well-timed trading opportunity, combining technical indicators with fundamental trends and a disciplined trading methodology should help you take the first steps towards investment success.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in SCLN with the Ticky from Trade-Ideas. See the FREE profile for SCLN NOW at Trade-Ideas

More details on SCLN:

If you liked this article you might like

Drug Price Inflation and a Patent Cliff Could Trigger a Wave of Deals in Generic Drugs Space

Merck Up on Approval, Teva Sinks on Earnings and Asset Sales: Biotech Movers

Today's Weak On High Volume Stock: SciClone Pharmaceuticals (SCLN)

SciClone Pharmaceuticals (SCLN): Today's Weak On High Volume Stock

Jim Cramer's 'Mad Money' Recap: Here's This Week's Game Plan